

NCT ID	NCT05627635
Title	FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer
Phase	Phase 1, Phase 2
Date Added	2022-11-25
Location	California, United States
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Balstilimab, Botensilimab, fluorouracil, Leucovorin Calcium, oxaliplatin
Tags	MSS/ MMRp
NCT ID	NCT04041310
Title	Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors
Phase	Phase 1, Phase 2
Date Added	2019-08-01
Location	California, United States Florida, United States Indiana, United States Maryland, United States Missouri, United States New York, United States Texas, United States Belgium Canada Italy Spain United Kingdom
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	
Tags	MSI-H/ MMRd
NCT ID	NCT05990543
Title	Combination of Nelmastobart and Capecitabine Therapy in Metastatic Colorectal Cancer
Phase	Phase 1, Phase 2
Date Added	2023-08-14
Location	South Korea
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Nelmastobart and Capecitabine
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT06011772
Title	A Phase 0 Study of EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer
Phase	Early Phase 1
Date Added	2023-08-25
Location	New York, United States
Prior IO Allowed	Yes
CRC-directed	Yes

Status	Active, not recruiting
Drugs	fluorouracil, Irinotecan, Leucovorin, oxaliplatin
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT06034860
Title	Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types
Phase	Phase 1
Date Added	2023-09-13
Location	California, United States Indiana, United States Missouri, United States New York, United States Virginia, United States
Prior IO Allowed	Yes
CRC-directed	No
Status	Active, not recruiting
Drugs	MT-8421, Nivolumab, Opdivo
Tags	MSI-H/ MMRd
NCT ID	NCT06105021
Title	Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor
Phase	Phase 1, Phase 2
Date Added	2023-10-27
Location	California, United States Connecticut, United States New York, United States Oregon, United States Tennessee, United States Texas, United States Washington, United States Wisconsin, United States
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Active, not recruiting
Drugs	AFNT-211
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT06106308
Title	Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation
Phase	Phase 2
Date Added	2023-10-30

Location	Arizona, United States Arkansas, United States California, United States Florida, United States Hawaii, United States Indiana, United States Kansas, United States Michigan, United States Minnesota, United States Missouri, United States Nevada, United States New York, United States Ohio, United States Oregon, United States Pennsylvania, United States Tennessee, United States Texas, United States Utah, United States Virginia, United States Washington, United States Wisconsin, United States
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Bevacizumab, FOLFIRI, FOLFOX, Onvansertib
Tags	MSS/ MMRp
NCT ID	NCT06107413
Title	Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab
Phase	Phase 2
Date Added	2023-10-30
Location	Arizona, United States Arkansas, United States California, United States Connecticut, United States Florida, United States Illinois, United States Indiana, United States Louisiana, United States Minnesota, United States North Carolina, United States Oregon, United States South Carolina, United States South Dakota, United States Texas, United States Virginia, United States Belgium Germany Israel Japan South Korea Spain Taiwan
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	ABBV-400, Bevacizumab, fluorouracil, Folinic acid, Irinotecan
Tags	MSS/ MMRp

NCT ID	NCT03223779
Title	Study of TAS-102 Plus Radiation Therapy for the Treatment of the Liver in Patients With Hepatic Metastases From Colorectal Cancer
Phase	Phase 1, Phase 2
Date Added	2017-07-21
Location	Massachusetts, United States
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Active, not recruiting
Drugs	
Tags	MSI-H/ MMRd, MSS/ MMRp

NCT ID	NCT05879822
Title	A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive
Phase	Phase 2
Date Added	2023-05-30
Location	Brazil China Georgia Greece Hungary New Zealand Romania South Africa Turkey (Türkiye)
Prior IO Allowed	No
CRC-directed	No
Status	Active, not recruiting
Drugs	INCB099280
Tags	MSI-H/ MMRd